BridgeBio (BBIO) CEO Neil Kumar awarded options and 104,313 RSUs

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. reported that Chief Executive Officer Neil Kumar received new equity awards on March 17, 2026. He was granted stock options for 40,570 shares of common stock at an exercise price of $70.94 per share, expiring on March 16, 2036.

He also received 104,313 restricted stock units (RSUs), each representing one share of common stock. Both the option and RSU awards vest in equal 1/16 installments beginning on May 16, 2026, then quarterly, as long as he continues serving the company or its subsidiaries.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kumar Neil

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,570	$0.00	--
Grant/Award	Restricted Stock Units	104,313	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 40,570 shares (Direct); Restricted Stock Units — 104,313 shares (Direct)

Footnotes (1)

1. 1/16th of the shares subject to this option vest and become exercisable on May 16, 2026, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$70.94	03/17/2026		A		40,570		(1)	03/16/2036	Common Stock	40,570	$0	40,570	D
Restricted Stock Units	(2)	03/17/2026		A		104,313		(3)	(3)	Common Stock	104,313	$0	104,313	D

Explanation of Responses:

1. 1/16th of the shares subject to this option vest and become exercisable on May 16, 2026, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

3. The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did BridgeBio (BBIO) CEO Neil Kumar receive?

Neil Kumar received stock options for 40,570 shares at a $70.94 exercise price and 104,313 restricted stock units. Both awards are tied to BridgeBio common stock and represent compensation, not open-market share purchases or sales.

How do Neil Kumar’s new BridgeBio (BBIO) stock options vest?

The options vest with 1/16 of the 40,570 underlying shares on May 16, 2026, then 1/16 quarterly. Vesting continues only if Kumar remains in service with BridgeBio Pharma, Inc. or its subsidiaries through each scheduled vesting date.

What are the terms of Neil Kumar’s BridgeBio (BBIO) RSU grant?

Kumar was granted 104,313 restricted stock units, each representing one share of common stock. 1/16 vests on May 16, 2026, with additional 1/16 portions vesting quarterly, conditioned on his continued service. The RSUs have no stated expiration date.

Are Neil Kumar’s new BridgeBio (BBIO) grants open-market share purchases?

No, these are compensation-related awards. The Form 4 shows option and RSU grants coded as acquisitions under transaction code A, meaning they were granted by BridgeBio rather than bought in the open market by the CEO.

When do Neil Kumar’s BridgeBio (BBIO) stock options expire?

The granted options for 40,570 shares carry an expiration date of March 16, 2036. They become exercisable gradually starting May 16, 2026, and must be exercised, if at all, before that expiration to convert into BridgeBio common stock.